Muutke küpsiste eelistusi

Toxicological Effects of Veterinary Medicinal Products in Humans: Complete Set [Shrink-wrapped pack]

(KNW Animal Health Consulting, UK)
  • Formaat: Shrink-wrapped pack, 876 pages, kõrgus x laius: 234x156 mm, kaal: 1595 g, No, Contains 2 hardbacks
  • Sari: Issues in Toxicology Volume
  • Ilmumisaeg: 29-Nov-2012
  • Kirjastus: Royal Society of Chemistry
  • ISBN-10: 1849736855
  • ISBN-13: 9781849736855
Teised raamatud teemal:
Toxicological Effects of Veterinary Medicinal Products in Humans: Complete SetSuurem pilt
  • Formaat: Shrink-wrapped pack, 876 pages, kõrgus x laius: 234x156 mm, kaal: 1595 g, No, Contains 2 hardbacks
  • Sari: Issues in Toxicology Volume
  • Ilmumisaeg: 29-Nov-2012
  • Kirjastus: Royal Society of Chemistry
  • ISBN-10: 1849736855
  • ISBN-13: 9781849736855
Teised raamatud teemal:
Püsilink: https://www.kriso.ee/db/9781849736855.html
Toxicological Effects of Veterinary Medicinal Products in Humans is the first definitive guide to discuss the adverse effects of veterinary medicinal products in humans. The chapters focus on occupational safety and consumer issues and examine the circumstances under which exposure is likely to occur. To be in context, it reviews this against the background of adverse health effects from other sources in the veterinary and farming professions. The book examines adverse drug effects reported to regulatory agencies (mainly the FDA’s Center for Veterinary Medicine) and then considers a series of individual drugs, including antibiotics, anaesthetics and organophosphorus compounds. The chapters also discuss the fundamental aspects of regulatory issues relating to safety assessment, and examine the manner in which user safety is assessed prior to authorisation/approval and what measures can be taken after authorisation/approval in the light of findings from pharmacovigilance activities. There is growing concern over the issue of antimicrobial resistance and the contribution made by veterinary medicinal products. This too is addressed along with the significance to human health and measures that can be taken to mitigate the effects (if any) of the use of antibiotics in animals e.g. prudent use measures. The book will be an essential resource for medical practitioners in hospitals and general practice, pharmaceutical industry scientists, analysts, regulators and risk managers.


Toxicological Effects of Veterinary Medicinal Products in Humans is the first definitive guide to discuss the adverse effects of veterinary medicinal products in humans.


Toxicological Effects of Veterinary Medicinal Products in Humans is the first definitive guide to discuss the adverse effects of veterinary medicinal products in humans.

Toxicological Effects of Veterinary Medicinal Products in Humans is the first definitive guide to discuss the adverse effects of veterinary medicinal products in humans. The chapters focus on occupational safety and consumer issues and examine the circumstances under which exposure is likely to occur. To be in context, it reviews this against the background of adverse health effects from other sources in the veterinary and farming professions. The book examines adverse drug effects reported to regulatory agencies (mainly the FDA's Center for Veterinary Medicine) and then considers a series of individual drugs, including antibiotics, anaesthetics and organophosphorus compounds. The chapters also discuss the fundamental aspects of regulatory issues relating to safety assessment, and examine the manner in which user safety is assessed prior to authorisation/approval and what measures can be taken after authorisation/approval in the light of findings from pharmacovigilance activities. There is growing concern over the issue of antimicrobial resistance and the contribution made by veterinary medicinal products. This too is addressed along with the significance to human health and measures that can be taken to mitigate the effects (if any) of the use of antibiotics in animals e.g. prudent use measures. The book will be an essential resource for medical practitioners in hospitals and general practice, pharmaceutical industry scientists, analysts, regulators and risk managers.

Muu info

Government vets, toxicologists, regulatory authorities.
Volume 1
Chapter 1 Occupational Health and Safety Among Veterinarians and Veterinary Workers
1(20)
1.1 Introduction
1(1)
1.2 Physical Injuries
2(6)
1.2.1 Accidents and Related Incidents
2(2)
1.2.2 Needlestick Injuries
4(1)
1.2.3 Zoonotic Diseases
5(1)
1.2.4 Dermatoses
5(1)
1.2.5 Allergies
6(1)
1.2.6 Neoplastic Diseases
6(1)
1.2.7 Specific Risks for Women
7(1)
1.2.8 Mental Health
7(1)
1.3 Conclusions
8(13)
References
8(13)
Chapter 2 Regulation of Veterinary Medicines
21(19)
2.1 Introduction
21(1)
2.2 Criteria for Evaluation and Authorisation of Veterinary Medicinal Products
22(2)
2.3 European Union Legislation
24(12)
2.3.1 The National Procedure
25(1)
2.3.2 The Mutual Recognition Procedure
25(2)
2.3.3 The Decentralised Procedure
27(1)
2.3.4 The Centralised Procedure
27(1)
2.3.5 Maximum Residue Limits
28(1)
2.3.6 Pharmacovigilance
29(7)
2.4 Conclusions
36(4)
References
37(3)
Chapter 3 Consumer Safety - Maximum Residue Limits
40(41)
3.1 Introduction
40(1)
3.2 Establishment of MRLs in the EU
41(5)
3.3 MRLs - Other Considerations
46(4)
3.4 The Joint FAO/WHO Expert Committee on Food Additives (JECFA)
50(1)
3.5 Practical Uses of MRLs
51(2)
3.6 Residues Surveillance
53(6)
3.6.1 Residues and Residues Studies
54(2)
3.6.2 Residues Surveillance for Veterinary Drugs in the UK
56(3)
3.7 Residues Avoidance
59(3)
3.8 Conclusions
62(19)
References
63(18)
Chapter 4 The Assessment of User Safety
81(36)
4.1 Introduction
81(2)
4.2 The Assessment Process
83(9)
4.2.1 Hazard Identification and Assessment
83(3)
4.2.2 Exposure Assessment
86(6)
4.3 Biological Monitoring
92(1)
4.4 Risk Assessment
93(2)
4.5 Risk Management
95(1)
4.6 Risk Communication
96(1)
4.7 Conclusions
97(20)
References
98(19)
Chapter 5 General Anaesthetics
117(33)
5.1 Introduction
117(1)
5.2 Human Health Concerns
118(1)
5.3 Inhalation Anaesthetics
118(6)
5.3.1 Nitrous Oxide
119(1)
5.3.2 Halothane
119(2)
5.3.3 Isoflurane
121(2)
5.3.4 Sevoflurane
123(1)
5.3.5 Enflurane
124(1)
5.4 Injectable Anaesthetics
124(6)
5.4.1 Propofol
124(2)
5.4.2 Barbiturates
126(1)
5.4.3 Etomidate
127(1)
5.4.4 Ketamine
128(2)
5.5 Conclusions
130(20)
References
130(20)
Chapter 6 Veterinary Products Containing Pesticide Active Ingredients
150(94)
6.1 Introduction
150(1)
6.2 Toxicity of Individual Substances
151(15)
6.2.1 Pyrethroids
151(13)
6.2.2 Overview of the Toxic Effects of the Pyrethroids in Animals
164(1)
6.2.3 Toxicity to Humans
165(1)
6.3 Imidacloprid
166(1)
6.3.1 Effects in Humans
167(1)
6.4 Organophosphorus Compounds
167(5)
6.4.1 Diazinon
168(2)
6.4.2 Azamethiphos
170(2)
6.5 Metaflumizone
172(2)
6.6 Indoxacarb
174(2)
6.7 Fipronil
176(3)
6.7.1 Toxicity to Humans
179(1)
6.8 Amitraz
179(3)
6.8.1 Toxicity to Humans
181(1)
6.9 Dicyclanil
182(2)
6.10 Cyromazine
184(3)
6.10.1 Effects in Humans
187(1)
6.11 Benzoylureas - Diflubenzuron/Lufenuron/Teflubenzuron
187(3)
6.12 Spinosad
190(2)
6.13 Macrocyclic Lactones
192(8)
6.13.1 Metabolism
194(1)
6.13.2 Toxicology
195(3)
6.13.3 Summary of Laboratory Animal Toxicity Studies
198(1)
6.13.4 Factors Affecting Toxicity
199(1)
6.14 Adverse Effects in Target Species
200(2)
6.15 Human Toxicity
202(1)
6.16 Conclusions
203(41)
References
203(41)
Chapter 7 Antineoplastic Drugs
244(29)
7.1 Introduction
244(1)
7.2 Classification of Antineoplastic Drugs
244(7)
7.2.1 The Alkylating Agents
245(1)
7.2.2 Inhibitors of Mitosis
245(1)
7.2.3 Antimetabolites
246(2)
7.2.4 Antibiotics
248(3)
7.2.5 Platinum Drugs
251(1)
7.3 Toxicity
251(5)
7.4 Conclusions
256(17)
References
256(17)
Chapter 8 Antimicrobial Drugs
273
8.1 Introduction
273(1)
8.2 The β-Lactam Drugs
274(40)
8.2.1 The Penicilins
274(2)
8.2.2 The Cephalosporins
276(4)
8.2.3 Aminoglycosides
280(2)
8.2.4 Aminocyclitols
282(1)
8.2.5 The Quinolones
283(2)
8.2.6 Macrolides
285(4)
8.2.7 The Phenicols
289(2)
8.2.8 Tetracyclines
291(7)
8.2.9 Polyether Ionophore Antibiotics
298(1)
8.2.10 Lincosamides
298(2)
8.2.11 Polymixins
300(1)
8.2.12 Pleuromutilins
301(1)
8.2.13 Bacitracin
302(1)
8.2.14 Avilamycin
303(1)
8.2.15 Trimethoprim, Baquiloprim and Sulfonamides
303(3)
8.2.16 Quinoxaline-N-Oxides
306(2)
8.2.17 Other Antibiotic Growth Promoters
308(1)
8.2.18 Nitrofurans
308(2)
8.2.19 Fusidic Acid
310(1)
8.2.20 Novobiocin
310(1)
8.2.21 Rifaximin
311(1)
8.2.22 Dapsone
312(1)
8.2.23 Chlorhexidine
313(1)
8.3 Conclusions
314
References 315(66)
Subject Index 381(48)
Volume 2
Chapter 9 Human Safety of Coccidiostats: A European Perspective
1(32)
Derek W. Renshaw
9.1 Introduction
1(1)
9.1.1 Coccidiosis, Coccidiostats and Anticoccidial Medicines
1(1)
9.1.2 Human Exposure
2(1)
9.1.3 Committees that Evaluate the Safety of Coccidiostats
2(1)
9.2 Approaches Taken to Ensure the Human Safety of Coccidiostats
2(3)
9.2.1 Consumer Safety
2(1)
9.2.2 User Safety
3(1)
9.2.3 Inconsistencies in the Values of ADIs
3(1)
9.2.4 Inconsistencies in the Approaches Used to Establish MRLs
4(1)
9.2.5 Cross-contamination of Feed with Coccidiostats
5(1)
9.3 The Safety of Authorised Coccidiostats
5(20)
9.3.1 Ionophoric Polyether Coccidiostats
5(10)
9.3.2 Non-ionophoric Coccidiostats
15(10)
9.3.3 Other Anticoccidial Substances
25(1)
9.4 Conclusions
25(8)
References
26(7)
Chapter 10 Organophosphorus Veterinary Medicines
33(38)
Timothy C. Marrs
10.1 Introduction
33(5)
10.2 Anticholinesterase Activity
38(1)
10.3 Clinical Effects
39(11)
10.3.1 Syndromes Associated with OP Exposure
39(5)
10.3.2 Other Effects of OPs
44(3)
10.3.3 Diagnostic Tests and Biomarkers
47(2)
10.3.4 Management of OP Poisoning
49(1)
10.4 Exposure and Regulatory Aspects
50(2)
10.4.1 European Union
50(1)
10.4.2 USA
51(1)
10.4.3 Interpretation of Regulatory Studies
51(1)
10.4.4 Pharmacovigilance
52(1)
10.5 Sheep Dips in the United Kingdom
52(2)
10.5.1 Introduction
52(1)
10.5.2 Treatments
53(1)
10.5.3 Organophosphate Plunge Dips
53(1)
10.6 Conclusion
54(17)
References
54(17)
Chapter 11 Antifungal Drugs
71(24)
11.1 Introduction
71(1)
11.2 Griseofulvin
72(2)
11.3 Amphotericin B and Other Polyenes
74(2)
11.4 The Azoles
76(4)
11.4.1 Steroidogenesis Inhibition
76(3)
11.4.2 Hepatotoxicity
79(1)
11.4.3 Other Effects
79(1)
11.5 Conclusions
80(15)
References
81(14)
Chapter 12 Antiparasitic Drugs
95(60)
12.1 Introduction
95(1)
12.2 Individual Drugs or Groups of Drugs
95(28)
12.2.1 The Benzimidazoles
95(3)
12.2.2 Levamisole
98(1)
12.2.3 Salicylanilides
99(2)
12.2.4 Clorsulon
101(1)
12.2.5 Tetrahydropyrimidines
102(2)
12.2.6 Pyrazinoisoquinolones
104(3)
12.2.7 Monepantel
107(1)
12.2.8 Piperazine
108(2)
12.2.9 Diethylcarbamazine
110(1)
12.2.10 Nitroxynil
111(1)
12.2.11 Halofuginone
112(1)
12.2.12 Nitroimidazoles
113(3)
12.2.13 Imidocarb
116(2)
12.2.14 The Trypanocidal Drugs - Isometamidium and Diminazene
118(4)
12.2.15 Emodepside
122(1)
12.3 Conclusions
123(32)
References
126(29)
Chapter 13 Some Other Pharmacologically Active Drugs
155(93)
13.1 Introduction
155(1)
13.2 Opiates and Synthetic Opiates
155(6)
13.2.1 Etorphine
155(2)
13.2.2 Butorphanol
157(1)
13.2.3 Buprenorphine
158(1)
13.2.4 Fentanyl
159(2)
13.3 Euthanasia Agents
161(1)
13.4 Neuroactive Steroids
161(2)
13.5 Sedative Agents
163(6)
13.5.1 α2-Receptor Adrenergic Agonists
163(3)
13.5.2 Phenothiazines
166(1)
13.5.3 Butyrophenone Neuroleptic Agents
167(2)
13.6 Carazolol
169(1)
13.7 Clenbuterol
170(5)
13.8 Non-steroidal Anti-inflammatory Drugs
175(5)
13.8.1 Gastrointestinal Effects
176(1)
13.8.2 Cardiac Effects
177(1)
13.8.3 Nephrotoxicity
178(2)
13.8.4 Phenylbutazone
180(1)
13.9 Tropane Alkaloids
180(2)
13.10 Local Anaesthetics
182(2)
13.11 Antiepileptic Drugs
184(1)
13.11.1 Potassium Bromide
184(1)
13.12 Substances with Hormonal Activity
185(9)
13.12.1 Insulin
185(2)
13.12.2 Steroid Hormones
187(7)
13.13 Corticosteroids
194(1)
13.14 Prostaglandins
195(3)
13.15 Somatotropins
198(1)
13.16 Conclusions
199(49)
References
202(46)
Chapter 14 Human Safety of Veterinary Vaccines
248(25)
14.1 Introduction
248(4)
14.2 Zoonotic Diseases
252(1)
14.3 Physical Injury - High-pressure Injection Injuries
253(2)
14.4 Human Consumer Safety of Vaccine Excipients
255(2)
14.5 Conclusions
257(16)
References
257(16)
Chapter 15 Adverse Drug Reactions in Humans - Data from Veterinary Pharmacovigilance Schemes
273(92)
15.1 Introduction
273(1)
15.2 The Suspected Adverse Reactions Reporting Scheme - United Kingdom
273(9)
15.2.1 Dog and Cat Products Containing Imidacloprid
275(1)
15.2.2 Sprays Containing Dichlorvos
276(1)
15.2.3 Organophosphorus Sheep Dips
276(6)
15.3 Adverse Reaction Reporting in the USA
282(73)
15.4 Conclusions
355(10)
References
355(10)
Chapter 16 Veterinary Medicines and the Environment
365(38)
16.1 Introduction
365(1)
16.2 Human Pharmaceuticals
366(1)
16.3 Veterinary Pharmaceuticals
366(10)
16.3.1 Regulation of Veterinary Medicinal Products and Environmental Safety
367(5)
16.3.2 Adverse Environmental Effects of Veterinary Medicinal Products
372(3)
16.3.3 Reporting of Environmental Adverse Events and Incidents with Veterinary Medicines
375(1)
16.4 Conclusions
376(27)
References
378(25)
Chapter 17 Potential Adverse Microbiological Effects of Antimicrobials
403(26)
P. Silley
17.1 Introduction
403(2)
17.2 Antimicrobial Resistance and Campylobacter Species
405(8)
17.2.1 Why is Campylobacter Important?
405(3)
17.2.2 What Do We Know About Resistance Development in Campylobacter?
408(5)
17.3 Acceptable Daily Intake of Antimicrobial Residues
413(7)
17.3.1 Steps in Determining the Need for a Microbiological ADI
415(1)
17.3.2 How the Data are Handled - Colonization Barrier
416(1)
17.3.3 Calculations
417(2)
17.3.4 How the Data are Handled - Resistance Development
419(1)
17.3.5 Guideline Revision
420(1)
17.4 Concluding Thoughts
420(9)
References
422(7)
Subject Index 429
Since 1984 Dr. Kevin Woodward's experience has been centred on all aspects of the evaluation and regulation of veterinary drugs, particularly from the point of view of safety evaluation, toxicology, user risk assessment and pharmacovigilance. He was a member of the Committee for Veterinary Medicinal Products (CVMP) until August 1996 and Chairman of its Safety of Residues Working Group from 1991 until 1996. He was a member of the Joint FAO/WHO Expert Committee on Food Additives (JECFA) and an invited expert to the Committee for the years 1988-1996. He has also been leader of the UK delegation to the Codex Committee on Residues of Veterinary Drugs in Food from 1993 to 1996. From September 1997 until September 1999, and again from 1999 until November 2001, he chaired IFAH-Europe's (formerly FEDESA's) Technical and Regulatory Committee and was elected to the Board of Directors of FEDESA in February 2002 and to the Board of Directors of NOAH (ex-officio), also in February 2002. Since 2008, he has been the Regulatory Officer for the EAVPT.